Last reviewed · How we verify
Interferon beta 1a, oral doxycycline
Interferon beta-1a enhances immune response against viral infections and autoimmune disease, while oral doxycycline provides broad-spectrum antibiotic and anti-inflammatory effects.
Interferon beta-1a enhances immune response against viral infections and autoimmune disease, while oral doxycycline provides broad-spectrum antimicrobial and anti-inflammatory effects. Used for Multiple sclerosis (interferon beta-1a component), Investigational combination therapy (specific indication unclear from available data).
At a glance
| Generic name | Interferon beta 1a, oral doxycycline |
|---|---|
| Also known as | Avonex |
| Sponsor | Louisiana State University Health Sciences Center Shreveport |
| Drug class | Cytokine + tetracycline antibiotic combination |
| Target | Interferon-beta receptor (IFNBR); doxycycline targets bacterial ribosomes and matrix metalloproteinases |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Interferon beta-1a is a cytokine that activates natural killer cells and macrophages to enhance antiviral immunity and modulate immune responses in conditions like multiple sclerosis. Doxycycline is a tetracycline antibiotic with additional anti-inflammatory properties that inhibit matrix metalloproteinases and reduce inflammatory cytokine production. The combination leverages immunomodulation and anti-inflammatory mechanisms, though this particular pairing is unconventional and likely represents a research or investigational protocol rather than a standard marketed formulation.
Approved indications
- Multiple sclerosis (interferon beta-1a component)
- Investigational combination therapy (specific indication unclear)
Common side effects
- Flu-like symptoms (interferon)
- Injection site reactions (interferon)
- Gastrointestinal upset (doxycycline)
- Photosensitivity (doxycycline)
- Hepatotoxicity
- Neutropenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: